QQQ   352.63 (+1.09%)
AAPL   179.79 (+1.11%)
MSFT   324.97 (+0.49%)
META   267.30 (+1.40%)
GOOGL   122.58 (+0.07%)
AMZN   124.75 (+2.90%)
TSLA   231.40 (+3.04%)
NVDA   386.47 (+3.13%)
NIO   7.67 (-1.16%)
BABA   86.69 (+1.65%)
AMD   121.73 (+3.31%)
T   15.98 (-0.75%)
F   13.55 (-0.29%)
MU   65.11 (-2.91%)
CGC   0.70 (-3.31%)
GE   106.99 (+0.86%)
DIS   92.39 (-0.14%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.25 (+0.33%)
NFLX   406.59 (+1.71%)
QQQ   352.63 (+1.09%)
AAPL   179.79 (+1.11%)
MSFT   324.97 (+0.49%)
META   267.30 (+1.40%)
GOOGL   122.58 (+0.07%)
AMZN   124.75 (+2.90%)
TSLA   231.40 (+3.04%)
NVDA   386.47 (+3.13%)
NIO   7.67 (-1.16%)
BABA   86.69 (+1.65%)
AMD   121.73 (+3.31%)
T   15.98 (-0.75%)
F   13.55 (-0.29%)
MU   65.11 (-2.91%)
CGC   0.70 (-3.31%)
GE   106.99 (+0.86%)
DIS   92.39 (-0.14%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.25 (+0.33%)
NFLX   406.59 (+1.71%)
QQQ   352.63 (+1.09%)
AAPL   179.79 (+1.11%)
MSFT   324.97 (+0.49%)
META   267.30 (+1.40%)
GOOGL   122.58 (+0.07%)
AMZN   124.75 (+2.90%)
TSLA   231.40 (+3.04%)
NVDA   386.47 (+3.13%)
NIO   7.67 (-1.16%)
BABA   86.69 (+1.65%)
AMD   121.73 (+3.31%)
T   15.98 (-0.75%)
F   13.55 (-0.29%)
MU   65.11 (-2.91%)
CGC   0.70 (-3.31%)
GE   106.99 (+0.86%)
DIS   92.39 (-0.14%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.25 (+0.33%)
NFLX   406.59 (+1.71%)
QQQ   352.63 (+1.09%)
AAPL   179.79 (+1.11%)
MSFT   324.97 (+0.49%)
META   267.30 (+1.40%)
GOOGL   122.58 (+0.07%)
AMZN   124.75 (+2.90%)
TSLA   231.40 (+3.04%)
NVDA   386.47 (+3.13%)
NIO   7.67 (-1.16%)
BABA   86.69 (+1.65%)
AMD   121.73 (+3.31%)
T   15.98 (-0.75%)
F   13.55 (-0.29%)
MU   65.11 (-2.91%)
CGC   0.70 (-3.31%)
GE   106.99 (+0.86%)
DIS   92.39 (-0.14%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.25 (+0.33%)
NFLX   406.59 (+1.71%)
TSE:PMN

ProMIS Neurosciences (PMN) Stock Forecast, Price & News

C$6.80
+0.19 (+2.87%)
(As of 06/7/2023 ET)
Compare
Today's Range
C$6.80
C$6.80
50-Day Range
C$6.35
C$11.00
52-Week Range
C$5.60
C$12.22
Volume
2,599 shs
Average Volume
1,951 shs
Market Capitalization
C$58.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PMN stock logo

About ProMIS Neurosciences (TSE:PMN) Stock

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

PMN Stock News Headlines

ProMIS Neurosciences (TSE:PMN) Trading Up 0.7%
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
PMN.TO - | Stock Price & Latest News | Reuters
PMN:CA ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. (PMN)
ProMIS at 52-Week High
Stocks in play: ProMIS Neurosciences Inc.
Stocks in play: ProMIS Neurosciences Inc
See More Headlines

PMN Price History

PMN Company Calendar

Last Earnings
5/15/2023
Today
6/08/2023
Next Earnings (Estimated)
8/11/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
C$-20,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$7,558.00
Cash Flow
C$0.48 per share
Book Value
C($0.72) per share

Miscellaneous

Free Float
N/A
Market Cap
C$58.34 million
Optionable
Not Optionable
Beta
1.15

Key Executives

  • Dr. Neil R. Cashman M.D. (Age 70)
    Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
    Comp: $99k
  • Mr. Daniel E. Geffken M.B.A. (Age 65)
    MBA, Chief Financial Officer
    Comp: $122.28k
  • Mr. Gavin T. Malenfant (Age 60)
    Chief Operating Officer
    Comp: $53.32k
  • Dr. Johanne Kaplan Ph.D.
    Chief Devel. Officer
  • Dr. Gail M. Farfel Ph.D. (Age 58)
    Chief Exec. Officer
  • Dr. Ernest D. Bush Ph.D.
    Head of Pharmacology/Toxicology & Sr. Consultant
  • Dr. David Wishart Ph.D.
    Chief Physics Officer
  • Mr. Dennis Chen Ph.D.
    Head of Manufacturing & Sr. Consultant
  • Dr. Larry Douglas Altstiel M.D. (Age 72)
    Ph.D., Chief Medical Officer













PMN Stock - Frequently Asked Questions

How have PMN shares performed in 2023?

ProMIS Neurosciences' stock was trading at C$6.10 at the beginning of 2023. Since then, PMN shares have increased by 11.5% and is now trading at C$6.80.
View the best growth stocks for 2023 here
.

When is ProMIS Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our PMN earnings forecast
.

How were ProMIS Neurosciences' earnings last quarter?

ProMIS Neurosciences, Inc. (TSE:PMN) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.78) earnings per share for the quarter.

What other stocks do shareholders of ProMIS Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Biocept (BIOC), Spectra7 Microsystems (SEV), Flexion Therapeutics (FLXN), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bonavista Energy Co. (BNP.TO) (BNP) and QEP Resources (QEP).

What is ProMIS Neurosciences' stock symbol?

ProMIS Neurosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PMN."

How do I buy shares of ProMIS Neurosciences?

Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is ProMIS Neurosciences' stock price today?

One share of PMN stock can currently be purchased for approximately C$6.80.

How much money does ProMIS Neurosciences make?

ProMIS Neurosciences (TSE:PMN) has a market capitalization of C$58.34 million and generates C$7,558.00 in revenue each year. The company earns C$-20,930,000.00 in net income (profit) each year or C($3.70) on an earnings per share basis.

How can I contact ProMIS Neurosciences?

ProMIS Neurosciences' mailing address is 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada. The official website for the company is www.promisneurosciences.com. The company can be reached via phone at +1-416-8476898.

This page (TSE:PMN) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -